Poxel Announces Its Participation in Upcoming Scientific Conferences
25 Aprile 2022 - 07:30AM
Business Wire
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare metabolic disorders,
today announces that the Poxel team will participate in several
upcoming scientific conferences in May 2022.
- 65th Annual Meeting of the Japan Diabetes Society JDS –
Kobe, Japan Date: May 12-14, 2022 Pascale Fouqueray, Executive
Vice President, Clinical Development and Regulatory Affairs at
Poxel will give an online presentation on Imeglimin entitled: “A
Novel Approach to the Development of Anti-Diabetic Drugs: From
Screening of Seeds to Their Pipeline development”.
- European Renal Association – Paris, France Date: May 25-28,
2022 Pascale Gluais Dagorn, Director, Pharmacology at Poxel,
will give an online presentation on PXL770 in polycystic kidney
disease entitled: "Preclinical Efficacy of Direct AMPK Activation
with a Novel Small Molecule – PXL770 – for the Treatment of
Autosomal Dominant Polycystic Kidney Disease".
- 5th Global NASH Congress – London, United Kingdom Date: May
26-27, 2022 Sebastien Bolze, Executive Vice President and Chief
Operating Officer at Poxel will attend in-person and give a
presentation on PXL065 in NASH entitled: “Preclinical and Early
Clinical Characterization of PXL065 – Deuterium-Stabilized
(R)-Pioglitazone – a Potential Novel Oral Therapy for NASH”.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company
developing innovative treatments for chronic serious diseases
with metabolic pathophysiology, including non-alcoholic
steatohepatitis (NASH) and rare disorders. Poxel has clinical
and earlier-stage programs from its adenosine
monophosphate-activated protein kinase (AMPK) activator and
deuterated TZD platforms targeting chronic and rare metabolic
diseases. For the treatment of NASH, PXL065
(deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2
trial (DESTINY-1). PXL770, a first-in-class direct AMPK
activator, has successfully completed a Phase 2a proof-of-concept
trial for the treatment of NASH, which met its objectives. For the
rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the
company intends to initiate Phase 2a proof of concept studies with
PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN).
TWYMEEG® (Imeglimin), Poxel’s first-in-class lead product
that targets mitochondrial dysfunction, has been approved and
launched for the treatment of type 2 diabetes in Japan. Poxel
expects to receive royalties and sales-based payments from Sumitomo
Pharma. Poxel has a strategic partnership with Sumitomo Pharma for
Imeglimin in Japan, China, South Korea, Taiwan and nine other
Southeast Asian countries. The Company intends to generate further
growth through strategic partnerships and pipeline development.
Listed on Euronext Paris, Poxel is headquartered in Lyon, France,
and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220424005034/en/
Investor relations / Media Aurélie Bozza Investor
Relations & Communication Senior Director
aurelie.bozza@poxelpharma.com +33 6 99 81 08 36 Elizabeth Woo
Senior Vice President, Investor Relations & Communication
elizabeth.woo@poxelpharma.com NewCap Emmanuel Huynh or Arthur
Rouillé poxel@newcap.eu +33 1 44 71 94 94
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Mar 2023 a Mar 2024